Reported Earnings • Jun 15
Second quarter 2026 earnings released: JP¥58.65 loss per share (vs JP¥13.36 loss in 2Q 2025) Second quarter 2026 results: JP¥58.65 loss per share (further deteriorated from JP¥13.36 loss in 2Q 2025). Revenue: JP¥678.0m (down 19% from 2Q 2025). Net loss: JP¥307.0m (loss widened 339% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Announcement • Mar 31
Morpho, Inc. (TSE:3653) announces an Equity Buyback for 140,000 shares, representing 2.67% for ¥110 million. Morpho, Inc. (TSE:3653) announces a share repurchase program. Under the program, the company will repurchase up to 140,000 shares, representing 2.67% of its issued share capital (excluding treasury stock), at ¥613 per share, for ¥110 million. The purpose of the program is to enhance capital efficiency and aim for the sustainable improvement of corporate value. New Risk • Mar 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (JP¥3.58b market cap, or US$22.5m). Reported Earnings • Mar 14
First quarter 2026 earnings released: JP¥71.21 loss per share (vs JP¥23.35 loss in 1Q 2025) First quarter 2026 results: JP¥71.21 loss per share (further deteriorated from JP¥23.35 loss in 1Q 2025). Revenue: JP¥474.0m (down 32% from 1Q 2025). Net loss: JP¥374.0m (loss widened 207% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Reported Earnings • Dec 16
Full year 2025 earnings released: JP¥14.69 loss per share (vs JP¥58.50 profit in FY 2024) Full year 2025 results: JP¥14.69 loss per share (down from JP¥58.50 profit in FY 2024). Revenue: JP¥3.36b (up 1.8% from FY 2024). Net loss: JP¥77.0m (down 126% from profit in FY 2024). Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Dec 12
Morpho, Inc., Annual General Meeting, Jan 29, 2026 Morpho, Inc., Annual General Meeting, Jan 29, 2026. New Risk • Sep 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.0% average weekly change). Market cap is less than US$100m (JP¥5.75b market cap, or US$39.1m). Reported Earnings • Sep 15
Third quarter 2025 earnings released: JP¥3.43 loss per share (vs JP¥8.19 profit in 3Q 2024) Third quarter 2025 results: JP¥3.43 loss per share (down from JP¥8.19 profit in 3Q 2024). Revenue: JP¥802.0m (down 1.2% from 3Q 2024). Net loss: JP¥18.0m (down 143% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jun 15
Second quarter 2025 earnings released: JP¥13.36 loss per share (vs JP¥39.76 profit in 2Q 2024) Second quarter 2025 results: JP¥13.36 loss per share (down from JP¥39.76 profit in 2Q 2024). Revenue: JP¥832.0m (down 6.1% from 2Q 2024). Net loss: JP¥70.0m (down 134% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 26% After last week's 26% share price decline to JP¥872, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 18x in the Software industry in Japan. Total loss to shareholders of 8.4% over the past three years. Reported Earnings • Mar 15
First quarter 2025 earnings released: JP¥23.35 loss per share (vs JP¥16.77 loss in 1Q 2024) First quarter 2025 results: JP¥23.35 loss per share (further deteriorated from JP¥16.77 loss in 1Q 2024). Revenue: JP¥699.0m (up 6.7% from 1Q 2024). Net loss: JP¥122.0m (loss widened 42% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 06
Full year 2024 earnings released: EPS: JP¥58.50 (vs JP¥58.49 loss in FY 2023) Full year 2024 results: EPS: JP¥58.50 (up from JP¥58.49 loss in FY 2023). Revenue: JP¥3.30b (up 39% from FY 2023). Net income: JP¥301.0m (up JP¥601.0m from FY 2023). Profit margin: 9.1% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to JP¥1,362, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 22x in the Software industry in Japan. Total returns to shareholders of 22% over the past three years. Reported Earnings • Dec 16
Full year 2024 earnings released: EPS: JP¥58.50 (vs JP¥58.49 loss in FY 2023) Full year 2024 results: EPS: JP¥58.50 (up from JP¥58.49 loss in FY 2023). Revenue: JP¥3.30b (up 39% from FY 2023). Net income: JP¥301.0m (up JP¥601.0m from FY 2023). Profit margin: 9.1% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Announcement • Dec 13
Morpho, Inc., Annual General Meeting, Jan 30, 2025 Morpho, Inc., Annual General Meeting, Jan 30, 2025. New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (JP¥8.22b market cap, or US$58.4m). Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 27% After last week's 27% share price decline to JP¥1,307, the stock trades at a trailing P/E ratio of 38.3x. Average trailing P/E is 20x in the Software industry in Japan. Total returns to shareholders of 2.3% over the past three years. New Risk • Jun 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 25% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥9.89b market cap, or US$62.8m). Reported Earnings • Jun 17
Second quarter 2024 earnings released: EPS: JP¥39.76 (vs JP¥22.23 loss in 2Q 2023) Second quarter 2024 results: EPS: JP¥39.76 (up from JP¥22.23 loss in 2Q 2023). Revenue: JP¥886.0m (up 62% from 2Q 2023). Net income: JP¥204.0m (up JP¥318.0m from 2Q 2023). Profit margin: 23% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Announcement • Apr 03
Morpho, Inc. to Report Fiscal Year 2024 Results on Dec 13, 2024 Morpho, Inc. announced that they will report fiscal year 2024 results on Dec 13, 2024 Reported Earnings • Mar 17
First quarter 2024 earnings released: JP¥16.77 loss per share (vs JP¥47.38 loss in 1Q 2023) First quarter 2024 results: JP¥16.77 loss per share (improved from JP¥47.38 loss in 1Q 2023). Revenue: JP¥655.0m (up 46% from 1Q 2023). Net loss: JP¥86.0m (loss narrowed 65% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 03
Full year 2023 earnings released: JP¥58.49 loss per share (vs JP¥130 loss in FY 2022) Full year 2023 results: JP¥58.49 loss per share (improved from JP¥130 loss in FY 2022). Revenue: JP¥2.38b (up 19% from FY 2022). Net loss: JP¥300.0m (loss narrowed 55% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Dec 17
Morpho, Inc., Annual General Meeting, Jan 30, 2024 Morpho, Inc., Annual General Meeting, Jan 30, 2024. Reported Earnings • Dec 16
Full year 2023 earnings released: JP¥58.49 loss per share (vs JP¥130 loss in FY 2022) Full year 2023 results: JP¥58.49 loss per share (improved from JP¥130 loss in FY 2022). Revenue: JP¥2.38b (up 19% from FY 2022). Net loss: JP¥300.0m (loss narrowed 55% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. New Risk • Nov 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 52% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (JP¥6.07b market cap, or US$40.3m). Reported Earnings • Sep 11
Third quarter 2023 earnings released: JP¥15.60 loss per share (vs JP¥34.51 loss in 3Q 2022) Third quarter 2023 results: JP¥15.60 loss per share (improved from JP¥34.51 loss in 3Q 2022). Revenue: JP¥522.0m (up 4.8% from 3Q 2022). Net loss: JP¥80.0m (loss narrowed 55% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings. Reported Earnings • Jun 12
Second quarter 2023 earnings released: JP¥22.23 loss per share (vs JP¥15.99 loss in 2Q 2022) Second quarter 2023 results: JP¥22.23 loss per share (further deteriorated from JP¥15.99 loss in 2Q 2022). Revenue: JP¥547.0m (up 4.0% from 2Q 2022). Net loss: JP¥114.0m (loss widened 39% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 11
First quarter 2023 earnings released: JP¥47.38 loss per share (vs JP¥42.54 loss in 1Q 2022) First quarter 2023 results: JP¥47.38 loss per share (further deteriorated from JP¥42.54 loss in 1Q 2022). Revenue: JP¥448.0m (up 17% from 1Q 2022). Net loss: JP¥243.0m (loss widened 11% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Announcement • Feb 09
Morpho, Inc.’s SoftNeuro Enables 19x Faster Inference of 3D Simulation on Fugaku Morpho, Inc. has provided deep learning inference engine SoftNeuro to a project promoted by the University of Tokyo, Tohoku University, and Kobe University to accelerate high-resolution galaxy formation simulations using deep learning on the supercomputer Fugaku. The result is approx. 19.2 times faster inference time and approx. 93% reduction in power consumption. About Conditions and Measured Values: SoftNeuro is used for 3D-Unet inference on Fugaku. Comparison of inference speed using TensorFlow (available as standard on Fugaku) and using SoftNeuro optimized for Fugaku. Each Fugaku uses 1 node (48 cores). Morpho will support further acceleration of 3D simulations (galaxy formation simulations) using deep learning on Fugaku through the project and collaboration. In addition, Morpho will continue to further improve the convenience and technical capabilities of “SoftNeuro” and develop technology on a global level to realize a fruitful culture through the provision of various services and solutions. Reported Earnings • Feb 02
Full year 2022 earnings released: JP¥130 loss per share (vs JP¥147 loss in FY 2021) Full year 2022 results: JP¥130 loss per share (improved from JP¥147 loss in FY 2021). Revenue: JP¥2.00b (up 15% from FY 2021). Net loss: JP¥668.0m (loss narrowed 16% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings. Reported Earnings • Dec 12
Full year 2022 earnings released: JP¥130 loss per share (vs JP¥147 loss in FY 2021) Full year 2022 results: JP¥130 loss per share (improved from JP¥147 loss in FY 2021). Revenue: JP¥2.00b (up 15% from FY 2021). Net loss: JP¥668.0m (loss narrowed 16% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Senior Director Kiyohito Nagata was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 11
Third quarter 2022 earnings released: JP¥34.51 loss per share (vs JP¥43.42 loss in 3Q 2021) Third quarter 2022 results: JP¥34.51 loss per share (improved from JP¥43.42 loss in 3Q 2021). Revenue: JP¥498.0m (up 21% from 3Q 2021). Net loss: JP¥177.0m (loss narrowed 25% from 3Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 46 percentage points per year, which is a significant difference in performance. Reported Earnings • Jun 13
Second quarter 2022 earnings released: JP¥15.99 loss per share (vs JP¥21.26 loss in 2Q 2021) Second quarter 2022 results: JP¥15.99 loss per share (up from JP¥21.26 loss in 2Q 2021). Revenue: JP¥526.0m (up 9.6% from 2Q 2021). Net loss: JP¥82.0m (loss narrowed 29% from 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Board Change • Apr 30
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Senior Director Kiyohito Nagata was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Mar 29
Morpho, Inc. to Report Fiscal Year 2022 Results on Dec 09, 2022 Morpho, Inc. announced that they will report fiscal year 2022 results on Dec 09, 2022 Reported Earnings • Mar 13
First quarter 2022 earnings: Revenues and EPS in line with analyst expectations First quarter 2022 results: JP¥42.54 loss per share (up from JP¥45.94 loss in 1Q 2021). Revenue: JP¥382.0m (up 14% from 1Q 2021). Net loss: JP¥220.0m (loss narrowed 11% from 1Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 04
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: JP¥147 loss per share (down from JP¥121 loss in FY 2020). Revenue: JP¥1.73b (down 17% from FY 2020). Net loss: JP¥793.0m (loss widened 22% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Reported Earnings • Dec 14
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: JP¥147 loss per share (down from JP¥121 loss in FY 2020). Revenue: JP¥1.73b (down 17% from FY 2020). Net loss: JP¥793.0m (loss widened 22% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance. Announcement • Sep 11
Morpho, Inc. (TSE:3653) announces an Equity Buyback for 300,000 shares, representing 5.54% for ¥360 million. Morpho, Inc. (TSE:3653) announces a share repurchase program. Under the program, the company will repurchase up to 500,000 shares, representing 5.54% of its issued share capital (excluding treasury stock), at ¥1,200 per share, for ¥360 million. The purpose of the program is to utilize the incentive plan to promote the growth of the group and to carry out a flexible capital policy according to the business environment The program will run until March 16, 2022. As of August 31, 2021, the company had 5,414,000 shares in issue (excluding treasury stock) and 1,817 shares in treasury. Reported Earnings • Jun 14
Second quarter 2021 earnings released: JP¥21.26 loss per share (vs JP¥10.77 profit in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: JP¥480.0m (down 24% from 2Q 2020). Net loss: JP¥115.0m (down 298% from profit in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 14
First quarter 2021 earnings released: JP¥45.94 loss per share (vs JP¥9.10 loss in 1Q 2020) The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: JP¥335.0m (down 30% from 1Q 2020). Net loss: JP¥248.0m (loss widened 406% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 86% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. Announcement • Mar 10
Morpho, Inc. to Report Fiscal Year 2021 Results on Dec 10, 2021 Morpho, Inc. announced that they will report fiscal year 2021 results on Dec 10, 2021 Reported Earnings • Feb 02
Full year 2020 earnings released: JP¥121 loss per share (vs JP¥62.97 profit in FY 2019) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: JP¥2.07b (down 21% from FY 2019). Net loss: JP¥652.0m (down 292% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 67% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings. Announcement • Jan 12
Morpho, Inc. to Report Q1, 2021 Results on Mar 12, 2021 Morpho, Inc. announced that they will report Q1, 2021 results on Mar 12, 2021 Is New 90 Day High Low • Dec 22
New 90-day low: JP¥1,371 The company is down 23% from its price of JP¥1,770 on 23 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Software industry, which is up 2.0% over the same period. Reported Earnings • Dec 15
Full year 2020 earnings released: JP¥121 loss per share The company reported a poor full year result with weaker earnings, revenues and control over expenses. Full year 2020 results: Revenue: JP¥2.07b (down 21% from FY 2019). Net loss: JP¥652.0m (down 292% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 67% per year but the company’s share price has only fallen by 32% per year, which means it has not declined as severely as earnings. Announcement • Dec 13
Morpho, Inc., Annual General Meeting, Jan 29, 2021 Morpho, Inc., Annual General Meeting, Jan 29, 2021. Announcement • Sep 21
Morpho, Inc.(TSE:3653) dropped from S&P Global BMI Index Morpho, Inc.(TSE:3653) dropped from S&P Global BMI Index Announcement • Jul 19
Morpho, Inc. to Report Q3, 2020 Results on Sep 11, 2020 Morpho, Inc. announced that they will report Q3, 2020 results on Sep 11, 2020